Fingerprint
Dive into the research topics of 'Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically